Pertinax provides sustained, controlled antimicrobial protection for medical devices, biomaterials and in topical formulations.
Pertinax Pharma are supported by an experienced management team and a highly skilled and versatile team of scientists.
Get in touch to learn more about our technology and to discuss how Pertinax might be used in your products.
Get In Touch
About Pertinax Pharma
Pertinax formed in 2015, as a spin-out from the University of Bristol. The technology was initially developed in the laboratory of Dr Michele Barbour, CEO. Michele is supported by an experienced management team and a dynamic and dedicated team of scientists.
Find out the latest news and information from Pertinax.
Pertinax Pharma are delighted to announce that they have secured funding from Innovation 4 Growth (I4G). I4G is a funding scheme managed by the University of the West of England and developed using the European Regional Development Fund. It … Read More about Pertinax awarded ERDF Innovation 4 Growth grant
Pertinax Pharma Ltd is delighted to announce the successful closing of its latest £860,000 funding round. The investment was provided by national investors Mercia Fund Managers and Perivoli Innovations, both following on, and new investor … Read More about Pertinax close successful funding round
A paper describing the use of finely divided chlorhexidine hexametaphosphate particles in a glass ionomer cement has this week been accepted for publication in Dental Materials, the leading international journal for dental materials. The … Read More about New research paper accepted by Dental Materials